Last Updated: 19 April 2026
COMPASS Pathways is a UK-incorporated, Nasdaq-listed biotechnology company developing COMP360 — a proprietary synthetic psilocybin — as a therapy for treatment-resistant depression (TRD) with later-stage work in post-traumatic stress disorder. Both COMP005 and COMP006 Phase 3 trials in TRD have hit their pre-specified primary endpoints, but the market's reaction to the magnitude of the MADRS difference has been negative and the shares have re-rated materially lower. The company is pursuing a rolling NDA submission targeted for Q4 2026 alongside a significant funding round completed in February 2026.
1. Company Snapshot
| Item | Detail |
|---|---|
| Full Name | COMPASS Pathways plc (UK-incorporated; US-listed ADR-equivalent ordinary shares) |
| Ticker | NASDAQ: CMPS |
| Sector | Biopharmaceutical — Psychedelic Medicine |
| Founded | 2016 |
| Headquarters | London, UK (US operations in New York) |
| CEO | Kabir Nath (appointed August 2022) |
| Chief Medical Officer | Prof. Guy Goodwin |
| Market Cap (early April 2026) | ~$713 million |
| FY2025 Revenue | $0 (pre-commercial) |
| FY2025 Net Loss | $(287.9) million |
| Cash & equivalents (31 Dec 2025) | $149.6 million (pre-February 2026 financing) |
| Shares outstanding | 128.92 million |
| Exchange | Nasdaq Global Select |
| Website | compasspathways.com |
2. Bull Case vs Bear Case
Bull Case
- Both COMP005 (single-dose, 258 patients) and COMP006 (multi-dose, 581 patients) Phase 3 trials have met their pre-specified primary endpoints; COMP005 showed a -3.6 MADRS difference versus placebo at six weeks (p<0.001) and COMP006 showed a -3.8 MADRS difference at nine weeks for the 25 mg arm versus 1 mg (p<0.001).
- 26-week durability data from COMP005 show that responders maintained benefit through week 26 after one or two doses, with 40% of retreated patients achieving remission.
- COMPASS raised approximately $141m in net proceeds from a February 2026 public offering plus around $200m from the February 2026 warrant exercise (35,059,448 shares), extending runway into 2028 and removing near-term financing risk.
- Rolling NDA submission is targeted for Q4 2026 and the company has Breakthrough Therapy Designation (granted 2018) which supports expedited FDA review.
- Commercial infrastructure is being built through partnerships with Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Journey Clinical and Mindful Health Solutions, addressing the integrated drug-plus-therapy delivery challenge.
Bear Case
- The magnitude of the MADRS treatment effect (-3.6 to -3.8 points) has been received as modest by the market; shares fell substantially following the Phase 3 read-outs.
- FDA scrutiny of the psychedelic-plus-therapy paradigm intensified after the August 2024 Complete Response Letter to Lykos Therapeutics on MDMA-assisted therapy for PTSD, which flagged therapist oversight, patient selection, durability and blinding as concerns.
- Psilocybin is a DEA Schedule I controlled substance; any commercial launch requires DEA scheduling action alongside FDA approval, adding regulatory complexity.
- Reimbursement for a therapy-paired psychedelic protocol is unproven; the addressable market and realised ASP remain uncertain and depend on the eventual label and delivery model.
- Recent warrant exercises and a public offering have increased the share count materially; further dilutive rounds are possible if read-outs or the FDA review slip.
3. What Does This Company Actually Do?
COMPASS develops COMP360, a proprietary synthetic formulation of psilocybin, to treat treatment-resistant depression — a term describing patients who have not responded to at least two adequate antidepressant trials in the current major depressive episode. The lead programme is administered as a single or two-dose 25 mg oral dose with supervised psychological support and monitoring. Parallel development in PTSD commenced in Q1 2026 following IND acceptance for the Phase 2b/3 COMP202 study.
The company is pre-revenue. Its intellectual property covers the crystalline polymorph Form A of psilocybin — a patent position upheld by the US Patent Trial and Appeal Board in 2023 — and the integrated psychological support framework used in its clinical trials and future commercial delivery. The delivery model packages drug product, therapist-supervised dosing sessions and a digital platform for monitoring and dosing logistics. Commercial drug manufacturing is handled by third-party contract manufacturing organisations.
Pipeline at a glance: COMP005 (single-dose Phase 3 TRD — primary endpoint achieved 2025); COMP006 (multi-dose Phase 3 TRD — primary endpoint achieved 17 February 2026, 26-week Part B expected early Q3 2026); COMP202 (Phase 2b/3 PTSD — IND accepted Q1 2026, enrolment to begin mid-2026).
4. The Business Model
Commercial model is integrated drug plus therapist-supervised dosing. The company is building a network of clinical delivery partners: Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Journey Clinical, Mindful Health Solutions and others. Manufacturing is outsourced to CMOs; specific partners are not disclosed.
Revenue will come post-approval from the pharmaceutical product (COMP360) and potentially from software / training services linked to therapist accreditation. Reimbursement — especially by US commercial payers — is unproven for psychedelic-plus-therapy paradigms. The August 2024 Lykos CRL has raised the bar for how the FDA evaluates psychedelic-assisted therapy, with implications for how COMPASS's COMP360 label and therapist protocol requirements may be structured.
Subsidy and regulatory-credit dependency: none material. The company has Breakthrough Therapy Designation (granted 2018), which confers regulatory engagement advantages but no cash funding.
5. Financial Health
| Metric | FY2025 | Recent |
|---|---|---|
| Revenue | $0 | n/a |
| Net loss | $(287.9)m | — |
| Cash & equivalents (31 Dec 2025) | $149.6m | — |
| Debt (reported) | $31.6m at 31 Dec 2025; ~$50.4m disclosed as of 24 Mar 2026 | — |
| Feb 2026 public offering (net) | — | ~$141m |
| Feb 2026 warrant exercise | — | 35,059,448 shares; ~$200m gross |
| Pro-forma cash runway | — | Into 2028 per management |
The 20 February 2026 public offering and the 26 February 2026 warrant exercise together delivered more than $340m in combined proceeds, taking pro-forma cash to roughly $490m before ongoing burn. Quarterly operating cash burn has been in the $70–90m range and is likely to rise as NDA preparation and commercial readiness accelerate.
6. Valuation & Market Data
| Metric | Value | As of |
|---|---|---|
| Share price | $5.98 | 15 Apr 2026 |
| Market capitalisation | ~$713 million | 4 Apr 2026 |
| Enterprise value | ~$844m (pre-Feb 2026 financings) / materially lower pro-forma cash adjusted | — |
| Price-to-sales | N/A (no revenue) | — |
| EV/EBITDA | N/A (negative) | — |
| 52-week range | Data not fully available publicly | — |
| Short interest (shares) | 8.89 million | 31 Mar 2026 |
| Short interest (% float) | ~9.6% (+39.5% vs 15 Mar) | 31 Mar 2026 |
| Days to cover | ~5 days | Feb 2026 data |
Short interest rose roughly 40% between 15 March and 31 March 2026, reflecting positioning around the multiple catalyst events in Q1 2026 (COMP006 read-out, FY2025 earnings, financings). Put/call ratio and options skew data are not available in the public sources used for this report.
7. What Are They Building / What's Coming?
COMP006 Part B (26-week). Expected early Q3 2026. This read-out will determine multi-dose durability — a key input for payer dossier and label discussions.
Rolling NDA submission. Targeted Q4 2026. COMPASS held a Type B meeting with the FDA in September 2025 and announced in Q3 2025 that the commercial launch plan had been accelerated by 9–12 months relative to prior guidance.
COMP202 PTSD. IND accepted in Q1 2026; Phase 2b/3 design comprises a 12-week blinded Part A and a 40-week open-label Part B with CAPS-5 as the primary endpoint. Enrolment is expected to begin mid-2026.
Commercial infrastructure. Partnership network and therapist training programmes continue to be built out through 2026 ahead of potential launch in 2027.
Management commentary. CEO Kabir Nath has framed the programme as "redefining rapidity and durability" of antidepressant response, with onset as early as the day after dosing and durability across at least six months following one or two doses. He welcomed the 18 April 2026 White House Executive Order on psychedelic research access as supportive of the regulatory environment.
8. Competitive Landscape
Psychedelic peers.
| Company | Lead asset | Mechanism | Stage |
|---|---|---|---|
| atai Life Sciences / Beckley | BPL-003 (intranasal) | Mebufotenin benzoate (5-HT2A) | Phase 2b endpoints hit; Phase 3 initiation mid-2026 |
| Definium / MindMed | DT120 (oral) | LSD-derivative, GAD indication | Phase 3; Breakthrough Therapy |
| GH Research | GH001 (inhaled) | 5-MeO-DMT for TRD | Clinical hold lifted Jan 2026 |
| Cybin | Multiple | Proprietary delivery plus imaging | Early stage |
| Lykos Therapeutics | MDMA-assisted therapy (PTSD) | MDMA | CRL Aug 2024 |
Non-psychedelic TRD competitors (approved). Janssen (Johnson & Johnson) Spravato (esketamine nasal spray) — FDA-approved for TRD and now approved as a standalone monotherapy (January 2025); Axsome Therapeutics Auvelity (dextromethorphan/bupropion) — rapid-acting oral NMDA antagonist combination; plus established SSRIs, SNRIs and adjunct antipsychotics.
Policy-impact analysis. The FDA's August 2024 CRL to Lykos on MDMA-assisted therapy highlighted concerns about abuse-related AE documentation, therapist protocol consistency, participant diversity, selection bias and durability. Since COMPASS's own delivery model is therapy-paired, the risk that FDA will apply similar scrutiny to COMP360 is non-trivial. Offset on 18 April 2026 by a White House Executive Order directing acceleration of FDA research and access pathways for psychedelic treatments, which the company publicly welcomed.
9. Leadership and Ownership
Kabir Nath — Chief Executive Officer since August 2022. Formerly President and CEO of Otsuka Pharmaceutical Europe and Senior Managing Director at Otsuka (now Sumitomo Pharma). Brings 30+ years of experience in pharma and medtech commercialisation.
Prof. Guy Goodwin — Chief Medical Officer. Emeritus Professor of Psychiatry, University of Oxford; previously held the WA Handley Chair; expertise in mood disorders and psychedelic medicine.
Founders. George Goldsmith and Ekaterina Malievskaia (together with Lars Christian Wilde) co-founded COMPASS in 2016; Goldsmith and Malievskaia stepped down from the board on 29 March 2024.
Major shareholders. atai Life Sciences (Peter Thiel-backed) disclosed ~20.8% as of November 2021 — current holding not publicly updated in sources used here. Peter Thiel was disclosed at 7.54% at the August 2020 IPO. Perceptive Advisors is among the long-standing institutional holders. Current public float is approximately 128.92m shares.
Insider transactions. Form 4 data for individual insiders in the last 12 months is not consolidated in the public sources used for this report. The most recent corporate share issuance was the 1 April 2026 inducement grant to 7 new non-executive hires of 117,445 stock options and 55,875 RSUs under Nasdaq Rule 5635(c)(4).
10. Risks and Challenges
Clinical efficacy perception. Market response to the magnitude of the Phase 3 MADRS treatment effect has been negative; reviewer and payer reception will drive the regulatory and commercial path.
Regulatory psychedelic paradigm. The Lykos CRL signalled a high FDA bar for therapy-paired psychedelic programmes. COMP360's therapist protocols, patient selection, durability and blinding are all within the regulator's area of focus.
DEA scheduling. Psilocybin is currently Schedule I; post-FDA approval, DEA rescheduling is required before commercial distribution can scale.
Reimbursement uncertainty. The integrated drug-plus-therapy delivery model is unproven at payer scale; pricing, coverage policies and step-therapy criteria will shape addressable market.
Cash runway. ~$490m pro-forma cash funds operations into 2028 on current burn, but any slippage in NDA timelines or commercialisation preparation lengthens the runway required.
Competitive risk. Multiple psychedelic programmes advancing (atai/Beckley BPL-003, Definium DT120, GH Research GH001), with Phase 3 read-outs clustering in 2026. Established TRD competitors (Spravato, Auvelity) have more mature commercial footprints.
Dilution. Recent warrant exercise and public offering increased share count materially; future financing rounds — if required — may be dilutive at depressed prices.
Political and policy risk. US administration posture on psychedelics has been positive in April 2026 but is subject to change; UK and EU regulatory paths are less advanced.
Key-person risk. CEO change in 2022 and founder departures in 2024 mark a meaningful strategic shift; continuity of clinical leadership (Goodwin as CMO) is important to maintain operational momentum.
11. Recent Developments
Last 48 hours (17–19 April 2026). No material new COMPASS-specific RNS or SEC filings detected. The 18 April White House Executive Order on psychedelic research and access — which the company publicly welcomed — is the most recent policy-level development.
April 2026. On 7 April 2026 the company announced inducement equity grants (117,445 options, 55,875 RSUs) to 7 new non-executive hires with a 1 April 2026 grant date. Participation in the Needham Virtual Healthcare Conference fireside chat took place on 14 April 2026.
March 2026. FY2025 annual report filed on 24 March 2026: $0 revenue, $(287.9)m net loss, $149.6m cash. On 8 March 2026 management reiterated the Phase 3 durability narrative at a conference, highlighting 26-week maintenance of benefit after one or two doses and 40% remission in retreated patients.
February 2026. On 17 February 2026 COMP006 Part A primary endpoint was achieved in 581 patients (25 mg arm: -3.8 MADRS difference versus 1 mg, p<0.001). On 20 February 2026 the company closed a public offering with net proceeds of approximately $141m. On 26 February 2026 warrant exercises resulted in 35,059,448 shares issued and approximately $200m of proceeds.
Earlier. COMP005 primary endpoint achieved Q1 2025 (258 patients, -3.6 MADRS at six weeks, p<0.001). Q3 2025: management announced commercial launch plan accelerated by 9–12 months following a Type B FDA meeting in September 2025.
12. Key Dates Coming Up
- Early Q3 2026: COMP006 Part B (26-week durability) read-out.
- Mid-2026: COMP202 Phase 2b/3 PTSD enrolment begins.
- Q4 2026: Rolling NDA submission target for COMP360 in TRD.
- Late 2026 / early 2027: Potential FDA action window on NDA.
- Next earnings release: Q1 2026 results, expected in May 2026.
- 2026–2027: Commercial launch preparation with Greenbrook and other therapy delivery partners.
Track CMPS on the ChartsView Live Charts, check biotech catalyst dates on the Economic Calendar, discuss positioning in the Forum, and see more company research on the Blog.
Disclaimer
This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.